Refining General Principles of Antiepileptic Drug Treatments for Epilepsy

Kim, Keun Tae; Kim, Dong Wook; Yang, Kwang Ik; Lee, Sang Kun; Byun, Jung-Ick; Seo, Jong-Geun; No, Young Joo; Kang, Kyung Wook; Kim, Daeyoung; Cho, Yong Won

doi:10.3988/jcn.2020.16.3.383

Cited by 12 publications

(4 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…About half of patients with newly diagnosed epilepsy achieve complete remission with their first ASM. 31 Additionally, up to 70% of patients requiring more than one ASM can be well-controlled. 6 Unfortunately, in resource-limited settings, up to 43% of individuals formally diagnosed with epilepsy do not receive ASMs.…”

Section: Challenges In Access To Epilepsy Care In Lac Countriesmentioning

confidence: 99%

Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Rubinos,

San-Juan,

Alva-Diaz

et al. 2024

Semin Neurol

View full text Add to dashboard Cite

The burden of epilepsy in the Latin America and the Caribbean (LAC) region causes a profound regional impact on the health care system and significantly contributes to the global epilepsy burden. As in many other resource-limited settings worldwide, health care professionals and patients with epilepsy in LAC countries face profound challenges due to a combination of factors, including high disease prevalence, stigmatization of epilepsy, disparities in access to care, limited resources, substantial treatment gaps, insufficient training opportunities for health care providers, and a diverse patient population with varying needs. This article presents an overview of the epidemiology of epilepsy and discusses the principal obstacles to epilepsy care and key contributors to the epilepsy diagnosis and treatment gap in the LAC region. We conclude by highlighting various initiatives across different LAC countries to improve epilepsy care in marginalized communities, listing strategies to mitigate treatment gaps and facilitate better health care access for patients with epilepsy by enhancing the epilepsy workforce.

show abstract

Section: Challenges In Access To Epilepsy Care In Lac Countriesmentioning

confidence: 99%

Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Rubinos,

San-Juan,

Alva-Diaz

et al. 2024

Semin Neurol

View full text Add to dashboard Cite

show abstract

“…The selection of the most suitable ASD is challenging and several parameters need to be taken into consideration, such as the type(s) of seizure(s) or syndrome(s), the pharmacological properties of the ASD(s), and the individual features of the patient [ 23 , 24 ]. Monotherapy is the gold-standard strategy in epilepsy treatment, since the use of a single drug facilitates the efficacy evaluation, reduces the toxicity, avoids the risk of drug interactions, improves compliance, minimizes the costs, and allows the control of seizures in the majority of responsive patients [ 25 , 26 ]. However, in the cases of ineffective control of seizures with monotherapy, polytherapy (adjunctive therapy) should be considered, being as “rational” as possible.…”

Section: Therapeutic Approachesmentioning

confidence: 99%

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

et al. 2023

View full text Add to dashboard Cite

Epilepsy is a chronic and complex condition and is one of the most common neurological diseases, affecting about 50 million people worldwide. Pharmacological therapy has been, and is likely to remain, the main treatment approach for this disease. Although a large number of new antiseizure drugs (ASDs) has been introduced into the market in the last few years, many patients suffer from uncontrolled seizures, demanding the development of more effective therapies. Nanomedicines have emerged as a promising approach to deliver drugs to the brain, potentiating their therapeutic index. Moreover, nanomedicine has applied the knowledge of nanoscience, not only in disease treatment but also in prevention and diagnosis. In the current review, the general features and therapeutic management of epilepsy will be addressed, as well as the main barriers to overcome to obtain better antiseizure therapies. Furthermore, the role of nanomedicines as a valuable tool to selectively deliver drugs will be discussed, considering the ability of nanocarriers to deal with the less favourable physical-chemical properties of some ASDs, enhance their brain penetration, reduce the adverse effects, and circumvent the concerning drug resistance.

show abstract

“…However, there is limited research investigating the specific AED usage patterns in this population. Understanding the types of AEDs used and their effectiveness can aid clinicians in optimizing treatment regimens and minimizing adverse effects [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Demographic and clinical characteristics, seizure disorders, and antiepileptic drug usage in different types of corpus callosum disorders: a comparative study in children

Fu,

Wu,

Chou

et al. 2024

Ital J Pediatr

View full text Add to dashboard Cite

Background This study aimed to investigate the demographic and clinical characteristics, types of seizure disorders, and antiepileptic drug usage among individuals with different types of corpus callosum disorders. Methods A total of 73 individuals were included in the study and divided into three groups based on the type of corpus callosum abnormality: hypoplasia (H), agenesis (A), and dysgenesis (D). Demographic data, including gender and preterm birth, as well as clinical characteristics such as seizure disorders, attention deficit hyperactivity disorder (ADHD), severe developmental delay/intellectual disability, and other brain malformations, were analyzed. The types of seizure disorders and antiepileptic drugs used were also examined. Results The H group had the highest number of participants (n = 47), followed by the A group (n = 11) and the D group (n = 15). The A group had the highest percentage of males and preterm births, while the D group had the highest percentage of seizure disorders, other brain malformations, and severe developmental delay/intellectual disability. The A group also had the highest percentage of ADHD. Focal seizures were observed in all three groups, with the highest proportion in the A group. Focal impaired awareness seizures (FIAS) were present in all groups, with the highest proportion in the D group. Generalized tonic-clonic seizures (GTCS) were observed in all groups, with the highest proportion in the H group. Different types of antiepileptic drugs were used among the groups, with variations in usage rates for each drug. Conclusion This study provided insights into the demographic and clinical characteristics, seizure disorders, and antiepileptic drug usage among individuals with different types of corpus callosum disorders. Significant differences were found between the groups, indicating the need for tailored management approaches. However, the study has limitations, including a small sample size and a cross-sectional design. Further research with larger sample sizes and longitudinal designs is warranted to validate these findings and explore the relationship between corpus callosum abnormality severity and clinical outcomes.

show abstract

Refining General Principles of Antiepileptic Drug Treatments for Epilepsy

Cited by 12 publications

References 41 publications

Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Epilepsy Care in Latin America and the Caribbean: Overcoming Challenges and Embracing Opportunities

Fighting Epilepsy with Nanomedicines—Is This the Right Weapon?

Demographic and clinical characteristics, seizure disorders, and antiepileptic drug usage in different types of corpus callosum disorders: a comparative study in children

Contact Info

Product

Resources

About